reverSASP Therapeutics creates innovative new drugs for aging-related diseases targeting senescent cells. With its deep understanding of underlining biology of aging-related diseases, it focuses on Senescence-associated secretory phenotype, or SASP, as a drug target.
MediPhone, Inc. is a company based in Minato, Japan, founded in 2014, that specializes in medical interpretation services aimed at overcoming language barriers in healthcare. The company offers a range of services including telephone and video medical interpretation, a medical translation application, and the dispatch of interpreters for advanced treatments and medical checkups. Additionally, MediPhone provides assistance with medical certificates, consent forms, and hospitalization guidance, ensuring that clients can access healthcare services seamlessly, regardless of language differences. Through its comprehensive offerings, MediPhone facilitates improved communication between medical personnel and patients, enhancing the overall healthcare experience.
Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
Modulus Co., Ltd., established in 2016 and based in Tokyo, Japan, specializes in drug discovery with a focus on developing small-molecule therapeutics for oncology, chronic inflammation, immune disorders, and rare genetic conditions. The company employs advanced computational techniques, including virtual screening and machine learning algorithms, to facilitate the rapid design and generation of drug candidates targeting high-value diseases. Modulus Discovery's innovative platform integrates biological insights with computational drug discovery expertise, allowing for dynamic simulations of proteins in solvated environments. The firm also has an office in Cambridge, Massachusetts, and boasts a team of experts in drug design and disease biology, many of whom have extensive research and development experience in leading pharmaceutical and biotechnology firms.
A10 Lab Inc. is a Tokyo-based company founded in 2016 that specializes in developing a self-improvement mobile application aimed at enhancing users' well-being through habit formation. The application employs a team-based approach, allowing users to form groups of five, fostering collaboration and accountability among participants. Through gamification and social encouragement, the platform helps individuals establish new routines and develop skills that contribute to their personal growth. A10 Lab's innovative solution not only aims to improve individual happiness but also enhances user engagement, ultimately benefiting businesses by increasing customer lifetime value. The app, known as 'Min Chale,' has received recognition on Google Play for its effectiveness in promoting positive behavior change.
FastDOCTOR is a subsidy system for infants and compulsory Education.
Braizon Therapeutics, Inc. is a Tokyo-based company focused on the research and development of innovative drug delivery technologies aimed at treating central nervous system disorders. Founded in 2015, the company leverages collaborative research from prominent academics, including Professor Kazunori Kataoka and Professor Takanori Yokota, to create methodologies that facilitate the delivery of therapeutic drugs across the blood-brain barrier. By developing new drugs, diagnostics, and life science reagents, Braizon Therapeutics seeks to address the challenges associated with treating incurable neuronal diseases, ultimately enhancing the effectiveness of therapies for patients suffering from these conditions.
Developer of high-intensity focused ultrasound therapy systems designed to revolutionize medical therapy for the treatment of cancer patients. The company offers precise tissue targeting and real-time imaging capabilities, enabling healthcare professionals specializing in oncology and non-invasive surgery to deliver effective treatments with enhanced accuracy and patient comfort.
Operator of a drug discovery and development company intended to make the world disease-free. The company's research leverages the power of the gut microbiome, which can be applied to fields of pharmaceutical, healthcare, functional food, and academia, enabling innovations in the treatment of patients and curing diseases.
RIN Institute Inc. engages in research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company was founded in 2016 and is based in Tokyo, Japan.
Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.
Modulus Co., Ltd., established in 2016 and based in Tokyo, Japan, specializes in drug discovery with a focus on developing small-molecule therapeutics for oncology, chronic inflammation, immune disorders, and rare genetic conditions. The company employs advanced computational techniques, including virtual screening and machine learning algorithms, to facilitate the rapid design and generation of drug candidates targeting high-value diseases. Modulus Discovery's innovative platform integrates biological insights with computational drug discovery expertise, allowing for dynamic simulations of proteins in solvated environments. The firm also has an office in Cambridge, Massachusetts, and boasts a team of experts in drug design and disease biology, many of whom have extensive research and development experience in leading pharmaceutical and biotechnology firms.
Mental Health Technologies is a company that provides standard measures to maintain the mental health of employees, which is one of the foundations of health management.
AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, founded in 2015. The company specializes in the research and development of nucleic acid-based drugs, focusing on innovative drug delivery system technologies. AccuRna aims to address refractory diseases that currently lack effective treatments by utilizing its advanced drug delivery systems. The company offers two platforms for delivering various types of nucleic acids, including short chain and long chain RNA, which encompass siRNA, ASO, miRNA, mRNA, and CRISPR-Cas. Through these technologies, AccuRna seeks to provide safe and efficient therapeutic solutions for patients suffering from challenging medical conditions.
Cytlimic Inc. is a biotechnology company based in Japan that focuses on the development of immunotherapy products, particularly cancer peptide vaccines. Founded in December 2016, the company specializes in the clinical trials and nonclinical testing of these vaccines, along with development and stability testing for investigational use. Cytlimic's innovative products are designed to activate the immune system to target and attack cancer cells, aiming to improve treatment outcomes while allowing patients to maintain a high quality of life during their therapy. By leveraging advanced knowledge in cancer immunology, Cytlimic seeks to provide effective solutions for cancer treatment.
PuREC is a developer of a culture technology intended to bring efficacy to the treatment process.The company leverages technology to develop rapidly changing cell therapies and mesenchymal stem cells therapies, enabling clients to fight a variety of diseases and change the future of transplantation medicine.
RIN Institute Inc. engages in research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company was founded in 2016 and is based in Tokyo, Japan.
EdiGENE Inc. is a biotechnology company that specializes in developing therapeutics for genetic disorders. Founded in 2016 and headquartered in Tokyo, Japan, with additional offices in Cambridge, Massachusetts, the company leverages its proprietary technologies, including clustered regularly interspaced short palindromic repeats (CRISPR) and guide nucleotide directed modulation (GNDM), to create innovative treatments. EdiGENE's focus is on addressing unmet medical needs through its advanced therapeutic solutions, supported by a strong foundation of intellectual property licensed from the University of Tokyo.
Veldt Inc. is a Tokyo-based company that specializes in developing wearable technology, particularly luxury smartwatches designed to enhance daily life. Founded in 2012, Veldt offers a range of products under the VELDT brand, including the innovative VELDT SERENDIPITY smartwatch, which combines analog design with smartphone connectivity. This device features a transparent display that provides users with essential data while promoting a lifestyle that encourages exploration beyond screen time. The company sells its products through physical stores in Japan and offers online sales internationally. With a focus on functional design and the Internet of Things, Veldt aims to create a positive impact on both individual users and society by integrating technology into everyday routines in a meaningful way.
PENTAS Inc. develops medical analysis software and devices. The company was founded in 2015 and is based in Tokyo, Japan. PENTAS Inc. operates as a subsidiary of Allm Inc.
MediPhone, Inc. is a company based in Minato, Japan, founded in 2014, that specializes in medical interpretation services aimed at overcoming language barriers in healthcare. The company offers a range of services including telephone and video medical interpretation, a medical translation application, and the dispatch of interpreters for advanced treatments and medical checkups. Additionally, MediPhone provides assistance with medical certificates, consent forms, and hospitalization guidance, ensuring that clients can access healthcare services seamlessly, regardless of language differences. Through its comprehensive offerings, MediPhone facilitates improved communication between medical personnel and patients, enhancing the overall healthcare experience.
Mental Health Technologies is a company that provides standard measures to maintain the mental health of employees, which is one of the foundations of health management.
YUKASHIKADO INC. develops personal nutrition testing products. It sells its products online. The company was founded in 2013 and is based in Tokyo, Japan.
Braizon Therapeutics, Inc. is a Tokyo-based company focused on the research and development of innovative drug delivery technologies aimed at treating central nervous system disorders. Founded in 2015, the company leverages collaborative research from prominent academics, including Professor Kazunori Kataoka and Professor Takanori Yokota, to create methodologies that facilitate the delivery of therapeutic drugs across the blood-brain barrier. By developing new drugs, diagnostics, and life science reagents, Braizon Therapeutics seeks to address the challenges associated with treating incurable neuronal diseases, ultimately enhancing the effectiveness of therapies for patients suffering from these conditions.
Modulus Co., Ltd., established in 2016 and based in Tokyo, Japan, specializes in drug discovery with a focus on developing small-molecule therapeutics for oncology, chronic inflammation, immune disorders, and rare genetic conditions. The company employs advanced computational techniques, including virtual screening and machine learning algorithms, to facilitate the rapid design and generation of drug candidates targeting high-value diseases. Modulus Discovery's innovative platform integrates biological insights with computational drug discovery expertise, allowing for dynamic simulations of proteins in solvated environments. The firm also has an office in Cambridge, Massachusetts, and boasts a team of experts in drug design and disease biology, many of whom have extensive research and development experience in leading pharmaceutical and biotechnology firms.
HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.
CellBank Corp. is a Tokyo-based company founded in 2004 that specializes in cell storage, regenerative medical technology, and the cosmetics sector. The company operates within the framework of regulations governing the safety of regenerative medicine, focusing on innovative solutions in the field. CellBank is dedicated to advancing technologies that support both medical and cosmetic applications, positioning itself as a key player in the intersection of these industries.
CellBank Corp. is a Tokyo-based company founded in 2004 that specializes in cell storage, regenerative medical technology, and the cosmetics sector. The company operates within the framework of regulations governing the safety of regenerative medicine, focusing on innovative solutions in the field. CellBank is dedicated to advancing technologies that support both medical and cosmetic applications, positioning itself as a key player in the intersection of these industries.
RIN Institute Inc. engages in research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company was founded in 2016 and is based in Tokyo, Japan.
NB Health Laboratory Co. Ltd. is a biotechnology company based in Kawaguchi, Japan, focused on the research and development of innovative drugs primarily targeting respiratory diseases, chronic inflammation, and infectious diseases. The company provides a research platform for screening small compounds in vitro and offers functional monoclonal antibodies. It engages in contract research, co-development, and licensing activities, and has developed DAP Kinase inhibitors aimed at addressing stroke and heart diseases. Additionally, NB Health Laboratory conducts research programs related to chronic obstructive pulmonary disease (COPD), aneurysms, and skin wrinkles, as well as drug and functional monoclonal antibody screening programs. Their products are designed for the treatment of vascular diseases, including atherosclerosis and stroke, as well as other conditions such as diabetes-related vascular disorders, COPD, and sleep disorders.
AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, founded in 2015. The company specializes in the research and development of nucleic acid-based drugs, focusing on innovative drug delivery system technologies. AccuRna aims to address refractory diseases that currently lack effective treatments by utilizing its advanced drug delivery systems. The company offers two platforms for delivering various types of nucleic acids, including short chain and long chain RNA, which encompass siRNA, ASO, miRNA, mRNA, and CRISPR-Cas. Through these technologies, AccuRna seeks to provide safe and efficient therapeutic solutions for patients suffering from challenging medical conditions.
EdiGENE Inc. is a biotechnology company that specializes in developing therapeutics for genetic disorders. Founded in 2016 and headquartered in Tokyo, Japan, with additional offices in Cambridge, Massachusetts, the company leverages its proprietary technologies, including clustered regularly interspaced short palindromic repeats (CRISPR) and guide nucleotide directed modulation (GNDM), to create innovative treatments. EdiGENE's focus is on addressing unmet medical needs through its advanced therapeutic solutions, supported by a strong foundation of intellectual property licensed from the University of Tokyo.
Veldt Inc. is a Tokyo-based company that specializes in developing wearable technology, particularly luxury smartwatches designed to enhance daily life. Founded in 2012, Veldt offers a range of products under the VELDT brand, including the innovative VELDT SERENDIPITY smartwatch, which combines analog design with smartphone connectivity. This device features a transparent display that provides users with essential data while promoting a lifestyle that encourages exploration beyond screen time. The company sells its products through physical stores in Japan and offers online sales internationally. With a focus on functional design and the Internet of Things, Veldt aims to create a positive impact on both individual users and society by integrating technology into everyday routines in a meaningful way.
Veldt Inc. is a Tokyo-based company that specializes in developing wearable technology, particularly luxury smartwatches designed to enhance daily life. Founded in 2012, Veldt offers a range of products under the VELDT brand, including the innovative VELDT SERENDIPITY smartwatch, which combines analog design with smartphone connectivity. This device features a transparent display that provides users with essential data while promoting a lifestyle that encourages exploration beyond screen time. The company sells its products through physical stores in Japan and offers online sales internationally. With a focus on functional design and the Internet of Things, Veldt aims to create a positive impact on both individual users and society by integrating technology into everyday routines in a meaningful way.
EdiGENE Inc. is a biotechnology company that specializes in developing therapeutics for genetic disorders. Founded in 2016 and headquartered in Tokyo, Japan, with additional offices in Cambridge, Massachusetts, the company leverages its proprietary technologies, including clustered regularly interspaced short palindromic repeats (CRISPR) and guide nucleotide directed modulation (GNDM), to create innovative treatments. EdiGENE's focus is on addressing unmet medical needs through its advanced therapeutic solutions, supported by a strong foundation of intellectual property licensed from the University of Tokyo.
HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.
NIL is a company developed innovative functional ultrafine particle technology based on many years of research experience.
Mental Health Technologies is a company that provides standard measures to maintain the mental health of employees, which is one of the foundations of health management.
ReasonWhy Inc., founded on July 7, 2011, is based in Japan and specializes in healthcare IT services. The company offers four main services: Whytlink, a social network designed for doctors; Findme, an online platform that facilitates second opinions by connecting doctors from Whytlink to patients; WhytPlot, a big-data analysis tool tailored for pharmaceutical manufacturers; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy aims to enhance communication and collaboration within the healthcare sector.
Cytlimic Inc. is a biotechnology company based in Japan that focuses on the development of immunotherapy products, particularly cancer peptide vaccines. Founded in December 2016, the company specializes in the clinical trials and nonclinical testing of these vaccines, along with development and stability testing for investigational use. Cytlimic's innovative products are designed to activate the immune system to target and attack cancer cells, aiming to improve treatment outcomes while allowing patients to maintain a high quality of life during their therapy. By leveraging advanced knowledge in cancer immunology, Cytlimic seeks to provide effective solutions for cancer treatment.
Cytlimic Inc. is a biotechnology company based in Japan that focuses on the development of immunotherapy products, particularly cancer peptide vaccines. Founded in December 2016, the company specializes in the clinical trials and nonclinical testing of these vaccines, along with development and stability testing for investigational use. Cytlimic's innovative products are designed to activate the immune system to target and attack cancer cells, aiming to improve treatment outcomes while allowing patients to maintain a high quality of life during their therapy. By leveraging advanced knowledge in cancer immunology, Cytlimic seeks to provide effective solutions for cancer treatment.
NB Health Laboratory Co. Ltd. is a biotechnology company based in Kawaguchi, Japan, focused on the research and development of innovative drugs primarily targeting respiratory diseases, chronic inflammation, and infectious diseases. The company provides a research platform for screening small compounds in vitro and offers functional monoclonal antibodies. It engages in contract research, co-development, and licensing activities, and has developed DAP Kinase inhibitors aimed at addressing stroke and heart diseases. Additionally, NB Health Laboratory conducts research programs related to chronic obstructive pulmonary disease (COPD), aneurysms, and skin wrinkles, as well as drug and functional monoclonal antibody screening programs. Their products are designed for the treatment of vascular diseases, including atherosclerosis and stroke, as well as other conditions such as diabetes-related vascular disorders, COPD, and sleep disorders.
ReasonWhy Inc., founded on July 7, 2011, is based in Japan and specializes in healthcare IT services. The company offers four main services: Whytlink, a social network designed for doctors; Findme, an online platform that facilitates second opinions by connecting doctors from Whytlink to patients; WhytPlot, a big-data analysis tool tailored for pharmaceutical manufacturers; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy aims to enhance communication and collaboration within the healthcare sector.
Braizon Therapeutics, Inc. is a Tokyo-based company focused on the research and development of innovative drug delivery technologies aimed at treating central nervous system disorders. Founded in 2015, the company leverages collaborative research from prominent academics, including Professor Kazunori Kataoka and Professor Takanori Yokota, to create methodologies that facilitate the delivery of therapeutic drugs across the blood-brain barrier. By developing new drugs, diagnostics, and life science reagents, Braizon Therapeutics seeks to address the challenges associated with treating incurable neuronal diseases, ultimately enhancing the effectiveness of therapies for patients suffering from these conditions.
AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, founded in 2015. The company specializes in the research and development of nucleic acid-based drugs, focusing on innovative drug delivery system technologies. AccuRna aims to address refractory diseases that currently lack effective treatments by utilizing its advanced drug delivery systems. The company offers two platforms for delivering various types of nucleic acids, including short chain and long chain RNA, which encompass siRNA, ASO, miRNA, mRNA, and CRISPR-Cas. Through these technologies, AccuRna seeks to provide safe and efficient therapeutic solutions for patients suffering from challenging medical conditions.
PuREC is a developer of a culture technology intended to bring efficacy to the treatment process.The company leverages technology to develop rapidly changing cell therapies and mesenchymal stem cells therapies, enabling clients to fight a variety of diseases and change the future of transplantation medicine.
CellSeed Inc. is a biotechnology company based in Tokyo, Japan, that specializes in the development of regenerative medicine products, focusing primarily on markets in Japan and Europe. Founded in 2001, the company conducts research, development, manufacturing, and marketing of cell-sheet regenerative medicines. Its product offerings include epithelial cell sheets for corneal and esophageal regeneration, regenerated cardiac patches for heart disease treatment, cell sheets for periodontal tissue regeneration, and regenerated cartilage sheets for osteoarthritis. Additionally, CellSeed provides innovative cell cultureware products designed for cell-sheet engineering and collection, as well as contract development and manufacturing services.
BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, dedicated to developing innovative cancer immunotherapy treatments. The company focuses on peptide vaccine technology designed to enhance the immune response against tumor-associated antigens. Its lead candidate, ITK-1, is a cancer peptide vaccine currently undergoing Phase III clinical trials for prostate cancer. In addition, BrightPath is advancing GRN-1201, which is in Phase II clinical trials for non-small cell lung cancer and Phase I trials for melanoma. The company is also researching GRN-1301, aimed at treating drug-resistant non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived regenerated NKT cells. Founded in 2003 and previously known as GreenPeptide Co., Ltd., BrightPath Biotherapeutics rebranded in July 2017 to reflect its focus on biotherapeutics.
Developer of molecular imaging technology. The company develops, manufactures, and distributes molecular imaging probe reagents for drug discovery.
Japan Medical Information Research Institute specializes in collecting and analyzing medical information and offers consulting services.
CellSeed Inc. is a biotechnology company based in Tokyo, Japan, that specializes in the development of regenerative medicine products, focusing primarily on markets in Japan and Europe. Founded in 2001, the company conducts research, development, manufacturing, and marketing of cell-sheet regenerative medicines. Its product offerings include epithelial cell sheets for corneal and esophageal regeneration, regenerated cardiac patches for heart disease treatment, cell sheets for periodontal tissue regeneration, and regenerated cartilage sheets for osteoarthritis. Additionally, CellSeed provides innovative cell cultureware products designed for cell-sheet engineering and collection, as well as contract development and manufacturing services.
Chiome Bioscience Inc. is a Tokyo-based company focused on drug discovery and development. Established in 2005, it specializes in innovative antibody generation technology, particularly through its ADLib System, which facilitates the production of monoclonal antibodies. The company offers various services, including protein expression and purification, stable cell line generation, and antibody generation for research institutions, universities, and pharmaceutical companies. Chiome's product pipeline includes several therapeutic antibodies targeting various cancers, such as liver cancer and triple-negative breast cancer, as well as conditions like diabetic macular edema. The company has also formed collaborations to enhance its research capabilities, including an agreement with Velabs Therapeutics. Originally launched to commercialize technology developed at RIKEN, Chiome has evolved through mergers and strategic shifts, transitioning from platform development to a focus on drug discovery and clinical studies.